“…Interleukin [IL]-6) there is growing evidence that complement activation plays a crucial role [ 6 ] as suggested by increased plasma levels of activation products (soluble C5b9 [sC5b-9], C5a) and complement deposits in the affected tissues of COVID-19 patients [ [7] , [8] , [9] , [10] , [11] , [12] , [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] ]. This finding is consistent with the complement involvement reported in several viral diseases including infections with other coronaviruses [ [27] , [28] , [29] ] and the suggested protective effects of complement blockade on COVID-19 [ 6 ].…”